[CLS] O
Identification O
of O
APC2 O
, O
a O
homologue O
of O
the O
adenomatous B
polyposis I
coli I
tumour I
suppressor O
. O
[SEP] O

[CLS] O
A O
common O
MSH2 O
mutation O
in O
English O
and O
North O
American O
HNPCC B
families O
: O
origin O
, O
phenotypic O
expression O
, O
and O
sex O
specific O
differences O
in O
colorectal B
cancer I
. O
[SEP] O

[CLS] O
For O
both O
sexes O
combined O
, O
the O
penetrances O
at O
age O
60 O
years O
for O
all O
cancers B
and O
for O
colorectal B
cancer I
were O
0 O
. O
[SEP] O

[CLS] O
Complete B
absence I
of I
C7 I
was O
also O
found O
in O
one O
sibling O
who O
had O
the O
clinical O
syndrome O
of O
meningococcal B
meningitis I
and O
arthritis B
as O
a O
child O
and O
in O
this O
siblings O
clinically O
well O
eight O
- O
year O
- O
old O
son O
. O
[SEP] O

[CLS] O
In O
addition O
, O
a O
significant O
excess O
risk O
of O
basal B
cell I
carcinoma I
was O
seen O
( O
standardized O
incidence O
ratio O
35 O
, O
95 O
% O
confidence O
interval O
7 O
. O
2 O
to O
102 O
) O
. O
[SEP] O

[CLS] O
An O
altered O
beta O
- O
alanine O
, O
uracil O
and O
thymine O
homeostasis O
might O
underlie O
the O
various O
clinical B
abnormalities I
encountered O
in O
patients O
with O
DPD B
deficiency I
. O
[SEP] O

[CLS] O
In O
one O
family O
there O
was O
evidence O
of O
non O
- O
penetrance O
and O
susceptibility O
to O
both O
gastric B
and I
colorectal I
cancer I
; O
thus O
, O
in O
addition O
to O
six O
cases O
of O
gastric B
cancer I
, O
a O
CDH1 O
mutation O
carrier O
developed O
colorectal B
cancer I
at O
age O
30 O
years O
. O
[SEP] O

[CLS] O
We O
report O
that O
heterozygosity O
for O
a O
targeted O
murine O
Wt1 O
allele O
, O
Wt1 O
( O
tmT396 O
) O
, O
which O
truncates O
ZF3 O
at O
codon O
396 O
, O
induces O
mesangial B
sclerosis I
characteristic O
of O
DDS B
in O
adult O
heterozygous O
and O
chimeric O
mice O
. O
[SEP] O

[CLS] O
The O
positive O
control O
for O
DMT1 O
up O
- O
regulation O
was O
a O
murine O
model O
of O
dietary B
iron I
deficiency I
that O
demonstrated O
greatly O
increased O
levels O
of O
duodenal O
DMT1 O
( O
IRE O
) O
mRNA O
. O
[SEP] O

[CLS] O
After O
treatment O
, O
the O
three O
patients O
with O
pure O
spinal B
abnormalities I
showed O
clinical O
and O
neurophysiologic O
worsening O
, O
whereas O
the O
two O
patients O
with O
a O
more O
advanced O
stage O
of O
disease O
( O
exhibited O
by O
SEPs O
) O
showed O
substantially O
unchanged O
clinical O
and O
neurophysiologic O
features O
. O
[SEP] O

[CLS] O
We O
extensively O
analyzed O
genomic O
DNA O
and O
messenger O
RNA O
( O
mRNA O
) O
from O
62 O
unrelated O
Korean O
patients O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
for O
identification O
of O
germline O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
mutations O
. O
[SEP] O

[CLS] O
Deficiency B
of I
the I
ninth I
component I
of I
human I
complement I
( O
C9 O
) O
is O
the O
most O
common O
complement B
deficiency I
in O
Japan O
, O
with O
an O
incidence O
of O
approximately O
one O
homozygote O
in O
1000 O
, O
but O
is O
very O
rare O
in O
other O
countries O
. O
[SEP] O

[CLS] O
HFE O
is O
the O
protein O
product O
of O
the O
gene O
mutated O
in O
the O
autosomal B
recessive I
disease I
hereditary B
hemochromatosis I
( O
Feder O
, O
J O
. O
[SEP] O

[CLS] O
Of O
17 O
unique O
APT1 O
mutations O
in O
unrelated O
ALPS B
probands O
, O
12 O
( O
71 O
% O
) O
occurred O
in O
exons O
7 O
- O
9 O
, O
which O
encode O
the O
intracellular O
portion O
of O
Fas O
. O
[SEP] O

[CLS] O
Multicentric O
origin O
of O
hemochromatosis B
gene O
( O
HFE O
) O
mutations O
. O
[SEP] O

[CLS] O
Non B
- I
syndromic I
hearing I
loss I
associated O
with O
enlarged B
vestibular I
aqueduct I
is O
caused O
by O
PDS B
mutations O
. O
[SEP] O

[CLS] O
Milder O
phenotypes O
such O
as O
adrenomyeloneuropathy B
and O
Addison B
disease I
only O
also O
have O
been O
recognized O
. O
[SEP] O

[CLS] O
Here O
, O
we O
explore O
the O
cell O
origin O
and O
aetiology O
of O
this O
common O
human O
skin B
tumour I
. O
[SEP] O

[CLS] O
Several O
novel O
as O
well O
as O
previously O
reported O
uncharacterized O
variants O
were O
also O
identified O
, O
some O
of O
which O
were O
associated O
with O
a O
family O
history O
of O
cancer B
. O
[SEP] O

[CLS] O
Heterozygous O
mutations O
in O
the O
CD95 O
( O
APO O
- O
1 O
/ O
Fas O
) O
receptor O
occur O
in O
most O
individuals O
with O
autoimmune B
lymphoproliferative I
syndrome I
( O
ALPS B
) O
and O
dominantly O
interfere O
with O
apoptosis O
by O
an O
unknown O
mechanism O
. O
[SEP] O

[CLS] O
Prenatal O
diagnosis O
by O
FISH O
in O
a O
family O
with O
Pelizaeus B
- I
Merzbacher I
disease I
caused O
by O
duplication O
of O
PLP O
gene O
. O
[SEP] O

[CLS] O
Together O
with O
the O
fact O
that O
both O
germ O
- O
line O
and O
sporadic O
APC B
mutations O
cluster O
in O
the O
central O
region O
of O
the O
APC B
gene O
, O
this O
points O
to O
a O
dominant O
negative O
effect O
of O
certain O
APC B
mutants O
. O
[SEP] O

[CLS] O
Changes O
at O
P183 O
of O
emerin O
weaken O
its O
protein O
- O
protein O
interactions O
resulting O
in O
X B
- I
linked I
Emery I
- I
Dreifuss I
muscular I
dystrophy I
. O
[SEP] O

[CLS] O
Microdeletions O
at O
chromosome O
bands O
1q32 O
- O
q41 O
as O
a O
cause O
of O
Van B
der I
Woude I
syndrome I
. O
[SEP] O

[CLS] O
No O
deletions O
were O
detected O
in O
seven O
cases O
of O
popliteal B
pterygia I
syndrome I
, O
76 O
cases O
of O
mixed O
syndromic B
forms I
of I
cleft I
lip I
and I
palate I
, O
and O
178 O
cases O
of O
nonsyndromic B
cleft I
lip I
and I
palate I
. O
[SEP] O

[CLS] O
We O
identified O
the O
alpha O
- O
cardiac O
actin O
gene O
( O
ACTC O
) O
as O
a O
novel O
disease O
gene O
in O
a O
pedigree O
suffering O
from O
familial B
hypertrophic I
cardiomyopathy I
( O
FHC B
) O
. O
[SEP] O

[CLS] O
Thus O
, O
the O
high O
frequency O
of O
mucosal B
overgrowth I
in O
AGU B
patients O
does O
not O
appear O
to O
be O
directly O
associated O
with O
lysosomal O
storage O
or O
with O
alterations O
in O
the O
level O
of O
AGA O
expression O
. O
[SEP] O

